Skip to content


Dificid, Dificlir (fidaxomicin) is a small molecule pharmaceutical. Fidaxomicin was first approved as Dificid on 2011-05-27. It is used to treat bacterial infections and pseudomembranous enterocolitis in the USA. It has been approved in Europe to treat clostridium infections. Dificid's patents are valid until 2034-05-28 (FDA).
Trade Name Dificlir
Common Name Fidaxomicin
Indication bacterial infections, clostridium infections, pseudomembranous enterocolitis
Drug Class Antibiotics (Micromonospora strains)
Get full access now